A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
Case Report of Breakthrough Long COVID and the Use of Nirmatrelvir-Ritonavir
[post]
2022
unpublished
Preserved Fulltext
Post-Acute Sequelae of SARS-CoV-2 (PASC), or long COVID, is a major public health problem. Encouraging data suggest that vaccination can reduce the risk of PASC. We report a cautionary case of breakthrough PASC and its resolution following a course of the novel combination antiviral nirmatrelvir-ritonavir.
doi:10.21203/rs.3.rs-1443341/v1
fatcat:lo4leycknva7rh5cd5ukveefci